# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN-TD
- Date: 1989-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week potassium and creatinine check, second hepatitis B vaccine, and same-day infectious diseases consultation. **S**

## History of present illness

Mr. Ashe returns four weeks after his first visit and is seen by Dr. Rao of infectious diseases on the same day. He takes bictegravir, emtricitabine, and tenofovir alafenamide each morning and trimethoprim-sulfamethoxazole twice a day, and has missed no doses. He started ezetimibe four weeks ago without muscle aches. He has had no headache, seizure, or weakness, and his right hand feels normal. He has had no rash, fever, cough, or breathlessness, and no chest pain. He is sleeping better than at the first visit and has started to coach again two afternoons a week. He has told no one new about his diagnosis and asked again that his results go only to him. **S**

| Element | Detail |
|---|---|
| Adherence | No missed doses of any medicine |
| New medicine | Ezetimibe for four weeks; no side effects |
| Neurological | No headache, seizure, or weakness |
| Heart | No chest pain; no nitroglycerin use |
| Privacy | Results to him only, by secure message |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or night sweats; weight up 0.6 kg |
| Integumentary | Negative | No rash on trimethoprim-sulfamethoxazole |
| Cardiovascular | Negative | No chest pain or palpitations |
| Neurological | Negative | No headache, seizure, numbness, or weakness |
| Psychiatric | Negative | Mood improving; sleeping better; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 72.6 kg; BMI 21.2 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 1.16 mg/dL; eGFR: 79 mL/min/1.73 m²; Glucose: 90 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.9 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.16 mg/dL at this visit **S**
- eGFR: 78 mL/min/1.73 m² at baseline, 79 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 90 mg/dL at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and composed; weight 72.6 kg, blood pressure 116/72 |
| Skin and mouth | No rash; no thrush |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | Grip strength and fine finger movements equal on both sides; no focal deficit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **HIV infection** (B20). Excellent adherence. Potassium 4.8 mmol/L and creatinine 1.16 mg/dL, unchanged from four weeks ago. The creatinine rise since before treatment (0.98 mg/dL) is expected: bictegravir and trimethoprim both block tubular secretion of creatinine without lowering the true filtration rate. Dr. Rao agrees with continuing the current regimen. **S**
   - Continue bictegravir, emtricitabine, and tenofovir alafenamide.
   - Viral load, CD4 count, blood count, metabolic panel, ALT, and lipids at three months.
   - Urine albumin-to-creatinine ratio with the three-month blood tests.
2. **Cerebral toxoplasmosis on maintenance therapy** (B58.2). No neurological symptoms; right hand normal. **S**
   - Continue trimethoprim-sulfamethoxazole until the CD4 count has been above 200 for more than six months with an undetectable viral load.
3. **Coronary artery disease after two bypass operations** (I25.10). No angina; blood pressure at goal; ezetimibe tolerated. **S**
   - Lipid panel with the three-month blood tests.
4. **Vaccines**. Second hepatitis B vaccine dose due today. **S**
   - Hepatitis B vaccine dose 2 given today.
   - Second meningococcal dose and first zoster dose at three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Up to date | 42 copies/mL four weeks ago, falling from 186,000 at diagnosis; next at three months |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Up to date | 156 cells/uL four weeks ago; next at three months |
| Laboratory | HIV genotype resistance test | At diagnosis, before ART; again if the viral load rebounds | Up to date | No resistance mutations on the genotype sent before ART in the hospital |
| Laboratory | HLA-B*5701 test | Only before abacavir is considered | Not indicated | Abacavir is avoided because of its association with myocardial infarction in people with coronary disease |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no antacid, calcium, iron, or new medicine |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Up to date | Hemoglobin 13.0 g/dL, white cells 4.2, platelets 198 four weeks ago; next at three months |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.8 mmol/L, creatinine 1.16 mg/dL, eGFR 79; stable |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Deferred | Not done when tenofovir alafenamide was started in the hospital or at intake, a deviation from the DHHS and HIVMA guidance. Creatinine is stable, so no harm is evident. Corrective action: urine albumin-to-creatinine ratio ordered with the three-month blood tests |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Up to date | ALT 30 U/L four weeks ago |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | Trimethoprim-sulfamethoxazole double strength twice daily, the alternative maintenance regimen; CD4 156, so it continues |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | Covered by the trimethoprim-sulfamethoxazole maintenance dose |
| Medication safety | Mycobacterium avium complex prophylaxis | Not recommended for people who start ART promptly | Not indicated | On fully active ART since the hospital |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms; grip and fine finger movements equal |
| Self-management | Hepatitis B vaccine series and antibody check | Two doses four weeks apart; surface antibody 1 to 2 months after the last dose | Completed today | Dose 2 given today; antibody check at three months |
| Self-management | Meningococcal ACWY vaccine | Two doses at least 8 weeks apart, then every 5 years | Up to date | Dose 1 four weeks ago; dose 2 at three months |
| Self-management | Live vaccines (MMR, varicella) | Contraindicated while CD4 below 200 | Not indicated | CD4 156; immune to measles, mumps, rubella, and varicella by serology in the hospital |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Results go to him alone by secure message; he has not chosen to tell anyone new; peer support group details given again |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Up to date | PHQ-9 5 four weeks ago; mood improving |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 116/72 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 72.6 kg, BMI 21.2; coaching two afternoons a week |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three; atorvastatin 80 mg has no interaction with bictegravir |
| Medication safety | Beta-blocker | First year after myocardial infarction, or with LVEF 50 percent or less, angina, or another indication | Not indicated | Myocardial infarction ten years ago; no angina, heart failure, or arrhythmia; blood pressure normal |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina; nitroglycerin not used; chest-pain plan reviewed |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Due | LDL 88 mg/dL at intake; ezetimibe added; recheck with the three-month blood tests |
| Laboratory | Lipoprotein(a), once in adulthood | Once in adulthood | Due | Not on record; with the three-month blood tests |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |
| Referral | Infectious diseases consultation | At diagnosis, then as advised | Completed today | Seen by Dr. Rao today |

## Goal progress

- HIV-1 viral load not detected by the three-month visit. In progress; target 1989-04-13. **S**
- CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely. In progress; target 1989-10-19. **S**
- LDL cholesterol below 55 mg/dL by the three-month visit. In progress; target 1989-04-13. **S**
- Hepatitis B vaccine series completed with a protective antibody level by the three-month visit. In progress; target 1989-04-13. **S**
- Keep blood pressure below 130/80 mmHg. In progress; target 1989-07-13. **S**

## Guideline basis

- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition), U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition), National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024), International Antiviral Society-USA (JAMA)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020), HIV Medicine Association of the Infectious Diseases Society of America (Clinical Infectious Diseases)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Three-month visit with blood and urine tests, the second meningococcal dose, and the first zoster dose. Results by secure message. **S**
- Next scheduled visit 1989-04-13: three-month HIV and lipid review. **S**
